Status:
COMPLETED
Effects of Single Plasma Exchange and Double Filtration Plasmapheresis (DFPP) on Peripheral Lymphocyte Phenotypes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Lead Sponsor:
Centre Hospitalier Universitaire de Nīmes
Conditions:
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
CIDP, a rare disorder affecting young adults, causes gradual weakness of the limbs, areflexia and impaired sensory function. New CIDP phenotypes without antibodies but with modified cell profiles have...
Eligibility Criteria
Inclusion
- Patients with confirmed Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) without pathogenic antibodies and stable under therapeutic plasmapheresis with one session every 2-3 weeks for at least two months.
- Patients who have given free written informed consent.
- Patients who have signed the consent form.
- Patients affiliated to or beneficiaries of a health insurance scheme.
- Adult patients (≥18 ans).
- Healthy subjects of the same age and sex
Exclusion
- Patients Under the age of 18.
- Patients under immunosuppressive treatment for less than 3 months.
- Patients participating in Category 1 research involving human subjects.
- Patients in an exclusion period determined by another study.
- Patients under legal protection, guardianship or curatorship.
- Patients unable to express consent.
- Patients for whom it is impossible to give informed information.
- Pregnant, parturient or breastfeeding patients.
- Healthy subject with chronic pathology or drug treatment
Key Trial Info
Start Date :
March 12 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 18 2023
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04742374
Start Date
March 12 2021
End Date
December 18 2023
Last Update
December 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Olivier MORANNE
Nîmes, France